New Research Collaboration Targets Role of CCL24 Protein in SSc

New Research Collaboration Targets Role of CCL24 Protein in SSc

307653

New Research Collaboration Targets Role of CCL24 Protein in SSc

Chemomab Therapeutics is teaming up with the University of Leeds to investigate the role of the protein CCL24 in scleroderma (SSc) — particularly how it contributes to blood vessel damage. Their findings may aid in the clinical development of CM-101, Chemomab’s first-in-class antibody designed to target and neutralize CCL24. A Phase 2 trial to test CM-101 in people with scleroderma, also known as systemic sclerosis, is planned to start early next year, Chemomab said in…

You must be logged in to read/download the full post.